Compare AbCellera Biologics Inc (ABCL) vs Morgan Stanley (MS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Morgan Stanley — how do they compare? AbCellera Biologics Inc trades at $7.19 (market cap $2.35B), while Morgan Stanley trades at $217.36 (market cap $350.22B). The key difference: Morgan Stanley is far larger — about 149× AbCellera Biologics Inc's market cap, and Morgan Stanley pays a 1.8% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MS | |
|---|---|---|
Market Cap | $2.35B | $350.22B |
Sector | Health | Financials |
52-Week High | $8.12 | $227.19 |
52-Week Low | $2.78 | $139.09 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Morgan Stanley (MS) trades at $222.10, up 3.82% today, near its consensus price target of $225.80. The stock shows strong fundamental momentum with three consecutive quarterly earnings beats and robust revenue growth, reaching $66.0B in 2025. Technical indicators are bullish, with the current price above key support levels. Recent news highlights the firm's role in leading Anthropic's IPO and expanding AI integration in wealth management.
The outlook remains positive given earnings outperformance and analyst consensus, though risks include volatile cash flows and high debt levels. Upside potential exists if the company maintains its growth trajectory and executes on strategic initiatives like the Anthropic IPO. Investors should monitor interest rate sensitivity and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
